Statement Of Cash Flows [Abstract]

BerGenBio - Filing #2615544

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	309,364,000 NOK	309,364,000 NOK	—	257,029,000 NOK	257,029,000 NOK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions	—	—	5,039,000 NOK	—	3,934,000 NOK	—	—
Adjustments for unrealised foreign exchange losses (gains)	—	—	667,000 NOK	—	710,000 NOK	—	—
Adjustments for share-based payments	—	—	7,113,000 NOK	—	7,412,000 NOK	—	—
Cash flows from (used in) operating activities	—	—	303,340,000 NOK	—	234,290,000 NOK	—	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	—	—	—	—	67,000 NOK	—	—
Interest received, classified as investing activities	—	—	3,130,000 NOK	—	3,614,000 NOK	—	—
Cash flows from (used in) investing activities	—	—	3,130,000 NOK	—	3,548,000 NOK	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	—	16,629,000 NOK	—	740,852,000 NOK	—	—
Payments of lease liabilities, classified as financing activities	—	—	565,000 NOK	—	585,000 NOK	—	—
Cash flows from (used in) financing activities	—	—	15,995,000 NOK	—	699,507,000 NOK	—	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	—	—	284,216,000 NOK	—	468,765,000 NOK	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	—	779,000 NOK	—	710,000 NOK	—	—
Cash and cash equivalents	436,646,000 NOK	—	—	721,641,000 NOK	—	—	253,586,000 NOK